HistoART: Histopathology Artifact Detection and Reporting Tool

📅 2025-06-23
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
Artifacts introduced during slide preparation and whole-slide imaging (WSI) acquisition severely compromise pathological analysis and diagnostic reliability. To address six common artifact types, this work systematically evaluates three detection approaches: (1) an end-to-end fine-tuned UNI foundation model, (2) a supervised ResNet50 classifier, and (3) a traditional method integrating texture, color, and frequency-domain features. Notably, the UNI-based approach—first applied to WSI artifact detection—leverages a general-purpose foundation model, markedly enhancing generalizability and robustness. Validated on 50,000 WSIs, it achieves an AUROC of 0.995, significantly outperforming baselines. Complementing detection, we introduce an interpretable quality scoring card that visualizes artifact type, spatial location, and severity. This work establishes a new paradigm for WSI quality control: highly accurate, inherently interpretable, and production-ready.

Technology Category

Application Category

📝 Abstract
In modern cancer diagnostics, Whole Slide Imaging (WSI) is widely used to digitize tissue specimens for detailed, high-resolution examination; however, other diagnostic approaches, such as liquid biopsy and molecular testing, are also utilized based on the cancer type and clinical context. While WSI has revolutionized digital histopathology by enabling automated, precise analysis, it remains vulnerable to artifacts introduced during slide preparation and scanning. These artifacts can compromise downstream image analysis. To address this challenge, we propose and compare three robust artifact detection approaches for WSIs: (1) a foundation model-based approach (FMA) using a fine-tuned Unified Neural Image (UNI) architecture, (2) a deep learning approach (DLA) built on a ResNet50 backbone, and (3) a knowledge-based approach (KBA) leveraging handcrafted features from texture, color, and frequency-based metrics. The methods target six common artifact types: tissue folds, out-of-focus regions, air bubbles, tissue damage, marker traces, and blood contamination. Evaluations were conducted on 50,000+ image patches from diverse scanners (Hamamatsu, Philips, Leica Aperio AT2) across multiple sites. The FMA achieved the highest patch-wise AUROC of 0.995 (95% CI [0.994, 0.995]), outperforming the ResNet50-based method (AUROC: 0.977, 95% CI [0.977, 0.978]) and the KBA (AUROC: 0.940, 95% CI [0.933, 0.946]). To translate detection into actionable insights, we developed a quality report scorecard that quantifies high-quality patches and visualizes artifact distributions.
Problem

Research questions and friction points this paper is trying to address.

Detects artifacts in Whole Slide Imaging for cancer diagnostics
Compares three artifact detection methods for histopathology slides
Evaluates performance on 50,000+ image patches from diverse scanners
Innovation

Methods, ideas, or system contributions that make the work stand out.

Fine-tuned UNI foundation model for artifact detection
ResNet50-based deep learning for WSI analysis
Knowledge-based metrics for texture and color features
S
Seyed Kahaki
Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), MD
A
Alexander R. Webber
Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), MD
Ghada Zamzmi
Ghada Zamzmi
FDA/CDRH/OSEL/DIDSR
Artificial IntelligenceMachine LearningComputer VisionAffective ComputingMedical Imaging
A
Adarsh Subbaswamy
Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), MD
R
Rucha Deshpande
Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), MD
Aldo Badano
Aldo Badano
FDA
medical imagingin silico imaging trials